Remogliflozin etabonate
http://dbpedia.org/resource/Remogliflozin_etabonate an entity of type: Thing
Remogliflozin etabonate (INN/USAN) is a drug of the gliflozin class for the treatment of non-alcoholic steatohepatitis ("NASH") and type 2 diabetes. Remogliflozin was discovered by the Japanese company Kissei Pharmaceutical and is currently being developed by , a wholly owned subsidiary of North Carolina USA-based , and Glenmark Pharmaceuticals through a collaboration with BHV. Remogliflozin was commercially launched first in India by Glenmark in May 2019.
rdf:langString
rdf:langString
Remogliflozin etabonate
xsd:integer
18775455
xsd:integer
1109068837
rdf:langString
none
xsd:integer
26
xsd:integer
442201
xsd:integer
494323
xsd:integer
8047110
xsd:integer
38
xsd:integer
5
rdf:langString
D10055
rdf:langString
Investigational
xsd:integer
2
xsd:integer
9
rdf:langString
OC1COCOcc2Cc3cccOCC
xsd:integer
1
rdf:langString
UAOCLDQAQNNEAX-ABMICEGHSA-N
rdf:langString
TR0QT6QSUL
rdf:langString
changed
xsd:integer
401621521
rdf:langString
Remogliflozin etabonate (INN/USAN) is a drug of the gliflozin class for the treatment of non-alcoholic steatohepatitis ("NASH") and type 2 diabetes. Remogliflozin was discovered by the Japanese company Kissei Pharmaceutical and is currently being developed by , a wholly owned subsidiary of North Carolina USA-based , and Glenmark Pharmaceuticals through a collaboration with BHV. Remogliflozin was commercially launched first in India by Glenmark in May 2019.
xsd:nonNegativeInteger
6810
xsd:string
442201-24-3
xsd:string
494323
xsd:string
TR0QT6QSUL
xsd:string
D10055